Fennec Pharmaceuticals Announces Second Closing of $20 Million Investment from Petrichor
~ Under the Terms of the Previously Announced Investment Agreement, $5 Million Already Funded Upon Initial Closing, Which Occurred on August 19, 2022, and $20 Million to be Funded Upon FDA Approval of PEDMARK® Which Occurred on September 20, 2022 ~
Related news for (FENC)
- Fennec Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update
- Fennec Pharmaceuticals Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update
- Fennec Pharmaceuticals Announces Commercial Launch of PEDMARQSI® In Germany
- Fennec Pharmaceuticals Announces Pedmarqsi® Positive Recommendation by NICE for the Prevention of Cisplatin-Induced Hearing Loss in England and Wales
- Fennec Pharmaceuticals Announces Early Partial Repayment of Its Outstanding Convertible Debt Facility with Petrichor Healthcare Capital Management